Generic drug giant Sandoz expects unbranded versions of Novo Nordisk's popular diabetes drug Ozempic to launch in Canada by the second quarter next year after a key patent expires, its CEO said on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback